Trial Profile
Multicenter, randomized study comparing the efficacy and safety of two doses of thalidomide (100 mg/day versus 400 mg/day) in the treatment of subjects with refractory or relapsed multiple myeloma
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Thalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 22 Oct 2019 Route and form of Thalidomide assumed fom RDI.
- 07 May 2008 New trial record.